HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Results for CTL/CD8+ T-Cell Epitope Variants

Filter results by Mutation Type:

GTLLLGMLMICSAVE gp160(18-32) mouse epitope
    LGMLMICSAVEKLWV gp160(22-36) mouse epitope
      LLMICSAT gp160(24-31) human epitope
        MICSAAEKLWVTVYYGVP gp160(26-43) human epitope
           NTAENLWVTVYYGVP gp160(29-43) B*44:02 human epitope
           SATEKLWVTVYYGVP gp160(29-43) human epitope
            AVEKLWVTVYY gp160(30-40) B*18:01 humanized mouse epitope
            AiEKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
            AaEKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
            AeEKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
            AVkKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
            AVgKLWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
            AVEKsWVTVYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
            AVEKLWVTiYY gp160(30-40) escape documented in this paper; inferred escape; observed variant
            AAENLWVTVYY gp160(30-40) B*44 human epitope
            AENLVWTVYY gp160(30-40) B44 human epitope
            AVEKLWVTVYYGVPA gp160(30-44) mouse epitope
            VMGNLWVTVYYGVPVWK gp160(30-46) C*07 human epitope
            AAENLWVTVYYGVPVWK gp160(30-46) human epitope
            vggNLWVTVYYGVPVWK gp160(30-46) subtype-specific susceptible form
            AAEQLWVTVYYGVPVWKEAT gp160(30-49) A11 human epitope
            AAEQLWVTVYYGVPVWKEAT gp160(30-49) A11 human epitope
            ATEKLWVTVYYGVPVWKEAT gp160(30-49) human epitope
            ATEKmWVTVYYGVPVWKEAT gp160(30-49) observed variant
            ATEKLWVTVYYGaPVWKEAT gp160(30-49) observed variant
            ATEKLcVTVYYGVPVWKEAT gp160(30-49) observed variant
            ATEKLWVTVhYGVPVWKEAT gp160(30-49) observed variant
            ATEKLWVTVYYGVPaWKEAT gp160(30-49) observed variant
            ATEKLWVTVYhGVPVWKEAT gp160(30-49) observed variant
             AENLWVTVY gp160(31-39) B*15:17 human epitope
             AENLWVTVY gp160(31-39) B*15:40 human epitope
             AENLWVTVY gp160(31-39) B*18 human epitope
             AENLWVTVY gp160(31-39) B*18:01 human epitope
             AdNLWVTVY gp160(31-39) susceptible form
             tdNLWVTVY gp160(31-39) susceptible form
             tEdLWVTVY gp160(31-39) escape documented in this paper
             eEdLWVTVY gp160(31-39) escape documented in this paper
             AEdsWVTVY gp160(31-39) escape documented in this paper
             AENLWVTVY gp160(31-39) B*18:01 human epitope
             AdNLWVTVY gp160(31-39) susceptible form
             AEdsWVTVY gp160(31-39) escape documented in this paper
             AENLWVTVY gp160(31-39) B*18:01 human epitope
             AENLWVTVY gp160(31-39) B*18:01 human epitope
             TEdLWVTVY gp160(31-39) escape documented in this paper
             eEDLWVTVY gp160(31-39) escape documented in this paper
             AEdsWVTVY gp160(31-39) escape documented in this paper
             AENLWVTVY gp160(31-39) B*44 human epitope
             AENLWVTVY gp160(31-39) B*44 human epitope
             AENLWVTVY gp160(31-39) B44 human epitope
             AENLWVTVY gp160(31-39) B44 human epitope
             AENLWVTVY gp160(31-39) B44 human epitope
             tENLWVTVY gp160(31-39) susceptible form
             AkNLWVTVY gp160(31-39) non-susceptible form
             AgNLWVTVY gp160(31-39) non-susceptible form
             AaNLWVTVY gp160(31-39) non-susceptible form
             AENLWVTVY gp160(31-39) B44 human epitope
             AENLWVTVY gp160(31-39) B44 human epitope
             AENLWVTVY gp160(31-39) B44 human epitope
             AENLWVTVY gp160(31-39) B*44:03 human epitope
             AaNLWVTaY gp160(31-39) diminished response
             AEkLWVTVY gp160(31-39) diminished response
             AENLgVTVY gp160(31-39) diminished response
             tENLWVTVY gp160(31-39) susceptible form
             vENsWVTVY gp160(31-39) diminished response
             tEkLWVTVY gp160(31-39) diminished response
             AgNLWVTVY gp160(31-39) diminished response
             AaNLWVTVY gp160(31-39) escape documented in this paper
             AkNLWVTVY gp160(31-39) escape documented in this paper
             tENLWVTiY gp160(31-39) susceptible form
             AENLWVTVY gp160(31-39) B*44:03 human epitope
             AEkLWVTVY gp160(31-39) escape documented in this paper
             tENLWVTVY gp160(31-39) susceptible form
             vENLWVTVY gp160(31-39) inferred escape
             AkNLWVTVY gp160(31-39) escape documented in this paper
             AgNLWVTVY gp160(31-39) escape documented in this paper
             AENLWVTiY gp160(31-39) observed variant
             AEdLWVTVY gp160(31-39) observed variant
             AaNLWVTVY gp160(31-39) escape documented in this paper
             AEsLWVTVY gp160(31-39) observed variant
             AdNLWVTVY gp160(31-39) observed variant
             AaNLWVTaY gp160(31-39) escape documented in this paper
             AENsWVTVY gp160(31-39) observed variant
             vENsWVTVY gp160(31-39) escape documented in this paper
             AEtLWVTVY gp160(31-39) observed variant
             tENLWVTiY gp160(31-39) susceptible form
             tEkLWVTVY gp160(31-39) escape documented in this paper
             AENLWVTVY gp160(31-39) C*02 human epitope
             AENLWVTVY gp160(31-39) human epitope
             AENLWVTVYY gp160(31-40) A*29 human epitope
             AENLWVTVYY gp160(31-40) A*68:02 human epitope
             AENLWVTVYY gp160(31-40) B*18 human epitope
             AENLWVTVYY gp160(31-40) B*44:02 human epitope
             AENLWVTVYY gp160(31-40) C*04 human epitope
             TEKLWVTVYYGVPVWKEATTTLFCA gp160(31-55) B18 human epitope
             TEKLWVTVYYGVPVWKEATTTLFCA gp160(31-55) B18 human epitope
              DNLWVTVYY gp160(32-40) B44 human epitope
              EKLWVTVYY gp160(32-40) C*06:02, C*07:02 human epitope
              ENLWVTVYY gp160(32-40) human epitope
              EQLWVTVYYGVPVWKEATTT gp160(32-51) human epitope
               KLWVTVYYGV gp160(33-42) A*02:01 human epitope
               KLWVTVYYGV gp160(33-42) A*02:01 human epitope
               KLWVTVYYGV gp160(33-42) A*02:01 human epitope
               NLWVTVYYGV gp160(33-42) A2 human epitope
               NLWVTVYYGV gp160(33-42) A2 human epitope
               kLWVTVYYGV gp160(33-42) observed variant
               qLWVTVYYGV gp160(33-42) observed variant
               dLWVTVYYGV gp160(33-42) observed variant
               KLWVTVYYGV gp160(33-42) A2 human epitope
               nwWVTVYYGV gp160(33-42) observed variant
                LWVTVYYGV gp160(34-42) A*02:01 human epitope
                LWVTVYYGV gp160(34-42) A*02:01 human epitope
                LWVTVYYGV gp160(34-42) A*02:01 human epitope
                LWVTVYYGVPVWKDA gp160(34-48) A*03:01 human epitope
                LWVTVYYGVPVWKEAKTT gp160(34-51) human epitope
                LWVTVYYGVPVWKEATTTLFCA gp160(34-55) A2 human epitope
                wWVTVYYGVPVWKEATnTLFCA gp160(34-55) observed variant
                LWVTVYYGVPVWKEATTTLFCA gp160(34-55) A2 human epitope
                  VTVYYGVPV gp160(36-44) A2 human epitope
                  VTVYYGVPV gp160(36-44) A2 human epitope
                  VTVYYGVPV gp160(36-44) A2 human epitope
                  VTVYYGVPVWK gp160(36-46) A*03:01 human epitope
                  VTVYYGVPVWR gp160(36-46) A*11 human epitope
                  VTVYYGVPVWR gp160(36-46) A11 human epitope
                  VTVYYGVPVWK gp160(36-46) A*68:01, A11 human epitope
                  VTVYYGVPVWK gp160(36-46) A*11:01 human, mouse epitope
                  VTVYYGVPVWr gp160(36-46) susceptible form
                  VTiYYGVPVWK gp160(36-46) susceptible form
                  VTVYdGVPVWK gp160(36-46) non-susceptible form
                  VTVYYGVPiWK gp160(36-46) susceptible form
                  iTVYYGVPVWr gp160(36-46) susceptible form
                  VTiYYGVPVWr gp160(36-46) susceptible form
                  VTVYdGVPVWr gp160(36-46) non-susceptible form
                  VTVYYGiPVWr gp160(36-46) susceptible form
                  VTVYYGVPVrr gp160(36-46) non-susceptible form
                  VTVYYGVPVWK gp160(36-46) A3 human epitope
                  VTVYYGVPVWK gp160(36-46) A3 supertype human, mouse epitope
                  VTVYYGVPVWK gp160(36-46) A*68:01 human epitope
                  VTVYYGVPVWr gp160(36-46) observed variant
                  VTVYYGVPVWKE gp160(36-47) A*03, A*11, A*68:01, C*07 human epitope
                   TVYYGVPVW gp160(37-45) A*03, A*11 human epitope
                   TVYYGVPVW gp160(37-45) B*35:01 human epitope
                   TVYYGVPVW gp160(37-45) B*57:03, B*58:01 human epitope
                   TVYYGIPVW gp160(37-45) human epitope
                   TVYYGVPVW gp160(37-45) human epitope
                   TVYYGVPVW gp160(37-45) human epitope
                   TVYYGVPMW gp160(37-45) human epitope
                   TVYYGVPVW gp160(37-45) human epitope
                   TVYYGVPVWK gp160(37-46) A*02, A*11 human epitope
                   TVYYGVPVWK gp160(37-46) A*03 human epitope
                   TVYYGVPVWK gp160(37-46) A*03 human epitope
                   TVYYGVPVWK gp160(37-46) A*03 human epitope
                   TVYYGVPVWK gp160(37-46) A*03 human epitope
                   TVYYGVPVWK gp160(37-46) A*03, A*11 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TiYYGVPVWK gp160(37-46) diminished response; escape documented in this paper; susceptible form
                   TiYYGVPVWr gp160(37-46) diminished response; escape documented in this paper; susceptible form
                   TVYYGVPagr gp160(37-46) diminished response; escape documented in this paper; susceptible form
                   TVhYGVPVWr gp160(37-46) diminished response; escape documented in this paper; non-susceptible form
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01 human epitope
                   TVYYGVPVWK gp160(37-46) A*03:01, A*68:01 human epitope
                   TVYYGVPVWr gp160(37-46) observed variant
                   TVYYGVPVWK gp160(37-46) A11 transgenic mouse epitope
                   TVYYGVPVWK gp160(37-46) A11, A3 human epitope
                   TVYYGVPVWK gp160(37-46) A11, A3 human epitope
                   TVYYGVPVMK gp160(37-46) A11, A3, A68 epitope
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWr gp160(37-46) susceptible form; subtype-specific susceptible form
                   TVYYGVPVWt gp160(37-46) susceptible form; subtype-specific susceptible form
                   aVYYGVPVWK gp160(37-46) susceptible form; subtype-specific susceptible form
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   AVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWK gp160(37-46) A3 human epitope
                   TVYYGVPVWK gp160(37-46) A*32 human epitope
                   TVYYGVPVWK gp160(37-46) A*34 human epitope
                   TVYYGVPVWK gp160(37-46) A*36 human epitope
                   TVYYGVPVWK gp160(37-46) A3 supertype human epitope
                   TVYYGVPVWK gp160(37-46) B*15:40 human epitope
                   TVYYGVPVWK gp160(37-46) B*18 human epitope
                   TVYYGVPVWK gp160(37-46) B*42:02 human epitope
                   TVYYGVPVWK gp160(37-46) human epitope
                   TVYYGVPVWKEAKTTLF gp160(37-53) A*32:01 human epitope
                   TVYYGVPVWKEAKTTLF gp160(37-53) A*43:01 human epitope
                   TVYYGVPVWKEAKTTLF gp160(37-53) B*58:01 human epitope
                   TVYYGVPVWKEAKTTLF gp160(37-53) C*18 human epitope
                   TVYYGVPVWKEATTTLF gp160(37-53) human epitope
                   TVYYGVPVWKEATTTLF gp160(37-53) human epitope
                   TVYYGVPVWKEAkTTLF gp160(37-53) subtype-specific susceptible form
                    VYYGVPVWKEA gp160(38-48) Cw7 human epitope
                    VYYGVPVWKEA gp160(38-48) Cw7 epitope
                    VYYGVPVWrEA gp160(38-48) observed variant
                    VYYGVPVWKEATTTL gp160(38-52) mouse epitope
                    VYYGVPVWKEATTTL gp160(38-52) mouse epitope
                     YYGVPVWKDAETTLF gp160(39-53) B*35:01, B*55:01 human epitope
                     YYGVPVWKeAtTTLF gp160(39-53) susceptible form
Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health